Filing summary
Entity and period: The supplied filing is for Oculus Innovative Sciences, Inc., not Sonoma Pharmaceuticals, Inc. It is a Form 10-Q for the quarter ended September 30, 2013, covering the three and six months ended on that date. The company’s fiscal year ends March 31; this is its fiscal second quarter. Amounts below are in U.S. dollars.
Business context
Oculus develops and sells healthcare products based primarily on its Microcyn technology, alongside laboratory testing services. It reported sales in 27 countries and operated across human and animal healthcare markets. The filing notes that the company did not have U.S. regulatory approval to market Microcyn as a drug or as a medical device with antimicrobial or wound-healing indications. Ruthigen, then a wholly owned subsidiary, was pursuing a planned initial public offering and development of a separate product candidate.
Financial performance and position
| Metric | Three months ended September 30, 2013 | Six months ended September 30, 2013 |
|---|---|---|
| Total revenue | $4.089 million, down 10% year over year | $7.461 million, down 13% |
| Gross profit | $2.705 million; product gross margin was 69%, versus 74% a year earlier | $4.905 million; product gross margin was 68%, versus 74% |
| Operating expenses | $3.976 million | $7.302 million |
| Operating loss | $1.271 million | $2.397 million |
| Net loss | $1.399 million, compared with $1.519 million | $3.111 million, compared with $1.074 million |
| Net loss per share | $0.21 | $0.47 |
Six-month product revenue fell 13% to $7.007 million. By region, U.S. product revenue declined 18% to $3.221 million and Mexico declined 14% to $2.776 million; Europe and the rest of the world increased 11% to $1.010 million. Licensing revenue rose to $830,000 for the six months, from $406,000. Product margins were pressured by lower margins associated with the More Pharma arrangement in Mexico.
At September 30, 2013, cash and cash equivalents were $3.190 million, total current assets $6.912 million, and working capital $2.175 million, down from $6.407 million at March 31. Total assets were $8.882 million and stockholders’ equity $1.550 million. Long-term debt, net of discounts and including its current portion, was reported at $1.092 million; a separate cash settlement liability was $309,000.
For the six months, operating cash flow was negative $2.454 million, investing cash flow negative $312,000, and financing cash flow negative $1.918 million. Cash declined $4.710 million from March 31. Financing cash outflow included $1.138 million of debt principal payments and $780,000 in deferred costs for Ruthigen’s planned offering.
Changes versus prior period
- Quarterly net loss improved by $120,000 year over year, despite lower revenue and product margins. Six-month net loss increased by $2.037 million, in part because the prior-year period included a $5.1 million More Pharma upfront payment that supported operating cash flow and was recognized over time as revenue.
- Six-month revenue weakness reflected U.S. and Mexico declines; the Mexico transition to More Pharma reduced sales prices and changed the timing and nature of sales. Lower Mexican selling expenses partly offset this pressure.
- Research and development expense increased to $1.390 million for six months, including $670,000 of Ruthigen-related expense. Management expected Ruthigen-related R&D and administrative costs to decrease after its planned IPO.
- Interest expense fell to $438,000 for six months, versus $568,000, as debt balances and related interest costs declined.
Outlook, risks and unusual items
- Liquidity and financing: Management said existing cash was expected to fund working capital and planned sales, marketing and R&D efforts through at least October 1, 2014. It also expected continuing losses and said additional capital could be needed for longer-term plans and debt obligations. No new financing commitment was secured; failure to obtain financing could require spending cuts or curtailment of R&D.
- Ruthigen offering contingency: The company expected reimbursement of $911,000 of Ruthigen-related costs if the planned IPO closed, including $824,000 recorded as deferred offering costs. The IPO was not assured; non-completion or delay could prevent or postpone repayment. The company also disclosed an agreement to arrange standby letters of credit securing scheduled lender payments before Ruthigen’s offering pricing.
- Nasdaq listing: Stockholders’ equity of $1.550 million was below the stated $2.5 million minimum under Nasdaq Capital Market Listing Rule 5550(b)(1). The company anticipated notice of non-compliance and said failure to regain compliance could lead to delisting and impair liquidity and access to capital.
- Debt and lender arrangements: Borrowings from Venture Lending & Leasing were secured by company assets, including intellectual property under one facility. A separate stock arrangement with the lenders generated a $210,000 six-month fair-value loss, while a $99,000 gain was recorded in the second quarter. Reported results therefore include non-cash fair-value movements.
- Customer concentration: For the six months, two customers accounted for 37% and 27% of revenue. At September 30, three customers represented 33%, 30% and 11% of net receivables.
- Legal and other commitments: The company disclosed a disputed Japan technology-license termination and a Mexico lawsuit; it had accrued no loss reserve for either. Potential severance under key-executive agreements was $1.843 million. Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
- Subsequent Ruthigen amendments: October and November 2013 amendments retained $5 million of milestone payments for the first product, tied to clinical and FDA-related events, and approximately $3 million of equipment purchases following the planned IPO. These amounts were contingent, not reported as current-period revenue.
Important facts for investors to verify
- Confirm the filing identity: the source is Oculus Innovative Sciences, Inc., despite the request metadata naming Sonoma Pharmaceuticals.
- Track cash use, working capital, and whether new capital is obtained before the company’s stated liquidity horizon.
- Verify whether Ruthigen’s IPO closed and whether the $911,000 of costs and other agreed expenses were reimbursed.
- Check Nasdaq compliance status given reported stockholders’ equity below the stated minimum.
- Assess revenue and margin trends by geography, the More Pharma economics, and the dependence on concentrated customers and partners.
- Review debt repayment, collateral and letter-of-credit requirements, along with the status of the disclosed legal matters.